Verve Therapeutics (VERV) Earnings Date, Estimates & Call Transcripts → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free VERV Stock Alerts $5.42 -0.18 (-3.21%) (As of 06/14/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 8EstimatedActual EPS (May. 8) -$0.59 Beat By $0.11 Consensus EPS (May. 8) -$0.70 Get Verve Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for VERV and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueVERV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VERV Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. Verve Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.79)($0.56)($0.68)Q2 20242($0.63)($0.58)($0.61)Q3 20242($0.65)($0.63)($0.64)Q4 20242($0.66)($0.59)($0.63)FY 20248($2.73)($2.36)($2.55)Q1 20252($0.67)($0.66)($0.67)Q2 20252($0.70)($0.63)($0.67)Q3 20252($0.71)($0.67)($0.69)Q4 20252($0.73)($0.68)($0.71)FY 20258($2.81)($2.64)($2.73)VERV Earnings Date and InformationVerve Therapeutics last posted its quarterly earnings data on May 8th, 2024. The reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.11. The firm earned $5.70 million during the quarter, compared to the consensus estimate of $2.11 million. Its revenue for the quarter was up 305.6% on a year-over-year basis. Verve Therapeutics has generated ($2.87) earnings per share over the last year (($2.87) diluted earnings per share). Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.73) to ($2.86) per share. Verve Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off prior year's report dates.Read More Verve Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/8/2024(Estimated)------- 5/8/2024Q1 2024($0.70)($0.59)+$0.11($0.59)$2.11 million$5.70 million2/27/2024Q4 2023($0.83)($0.69)+$0.14($0.69)$3.95 million$5.14 million11/7/2023Q3 2023($0.90)($0.72)+$0.18($0.72)$0.96 million$3.10 million 8/10/2023Q2 2023($0.90)($0.87)+$0.03($0.87)$0.67 million$2.10 million5/15/2023Q1 2023($0.77)($0.84)($0.07)($0.84)$1.00 million$1.40 million3/2/2023Q4 2022($0.76)($0.67)+$0.09($0.67)$1.50 million$1.01 million Get the Latest News and Ratings for VERV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/7/2022Q3 2022($0.75)($0.79)($0.04)($0.79)$5.00 million$0.93 million8/9/2022Q2 2022($0.63)($0.84)($0.21)($0.84)--5/10/2022Q1 2022($0.63)($0.62)+$0.01($0.62)--3/14/2022Q4 2021($0.54)($0.65)($0.11)($0.65)--11/10/2021Q3 2021($0.45)($0.47)($0.02)($0.47)--8/12/2021Q2 2021($0.53)($2.13)($1.60)$2.40-- Verve Therapeutics Earnings - Frequently Asked Questions When is Verve Therapeutics's earnings date? Verve Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates. Learn more on VERV's earnings history. Did Verve Therapeutics beat their earnings estimates last quarter? In the previous quarter, Verve Therapeutics (NASDAQ:VERV) reported ($0.59) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.70) by $0.11. Learn more on analysts' earnings estimate vs. VERV's actual earnings. How much revenue does Verve Therapeutics generate each year? Verve Therapeutics (NASDAQ:VERV) has a recorded annual revenue of $11.76 million. How much profit does Verve Therapeutics generate each year? Verve Therapeutics (NASDAQ:VERV) has a recorded net income of -$200.07 million. VERV has generated -$2.87 earnings per share over the last four quarters. What is Verve Therapeutics's EPS forecast for next year? Verve Therapeutics's earnings are expected to decrease from ($2.73) per share to ($2.86) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Protagonist Therapeutics Earnings NewAmsterdam Pharma Earnings Harmony Biosciences Earnings Edgewise Therapeutics Earnings Taro Pharmaceutical Industries Earnings Syndax Pharmaceuticals Earnings Ardelyx Earnings Kura Oncology Earnings Dynavax Technologies Earnings Schrödinger Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple Stock All-Time Highs: Can AI Outweigh Earnings Jitters?CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry Shifts This page (NASDAQ:VERV) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.